Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Infliximab Biosimilar CMAB008 vs Remicade in Healthy Subjects
NCT04779892Phase 1Completed
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Feb 2020
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of infliximab-axxq in rheumatoid arthritis (RA) (2 arms), sponsored by Taizhou Mabtech Pharmaceutical. Primary endpoint: Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours. Started Feb 2020; status: completed.
02
Drugs
infliximab-axxq
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04779892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04779892.